Finnair Plc Stock Exchange Release 2 June 2014 at 14.50 EET Finnair corrects the new financial guidance: Finnair estimates its 2014 turnover to be significantly lower than in 2013. Finnair lowers its turnover guidance for 2014 Finnair lowers its turnover guidance for 2014 due to the weaker than expected unit revenue development. New financial guidance: The ongoing uncertain economic outlook in Europe and Asia is contributing to weak consumer demand in our main markets. Air traffic is expected to grow moderately in 2014. Finnair, however, will not be able to benefit from that growth without progress in its cost savings program and its target cost structure in place. Finnair estimates its 2014 turnover to be significantly lower than in 2013. Fuel costs are expected to remain high. The outcome of Finnair's ongoing employee consultations and cost-saving negotiations will have a significant impact on financial performance in 2014, and therefore the company will reconsider giving guidance for its full-year 2014 financial performance after the savings negotiations have been concluded. Previous financial guidance: The ongoing uncertain economic outlook in Europe and Asia is contributing to weak consumer demand in our main markets. Air traffic is expected to grow moderately in 2014. Finnair, however, will not be able to benefit from that growth without progress in its cost savings program and its target cost structure in place. Finnair estimates its turnover to be close to the previous year’s level in 2014. Fuel costs are expected to remain high. The outcome of Finnair's ongoing employee consultations and cost-saving negotiations will have a significant impact on financial performance in 2014, and therefore the company will reconsider giving guidance for its full-year 2014 financial performance after the savings negotiations have been concluded. FINNAIR PLC Further information: Finnair communications, 358 9 818 4020, comms(a)finnair.com Distribution: NASDAQ OMX Helsinki Principal media
Correction: Finnair lowers its turnover guidance for 2014
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
OnTime's Bold Vision: Transforming Home Healthcare Admin
Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...
Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials
Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....
Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline
Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...
Continue Reading
Miral Impact Fund: A New Era for Community and Environment
Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...
Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors
Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...
Continue Reading